



The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains

Noortje de Haan¹, Karli R. Reiding¹, Jasminka Krištić², Agnes L. Hipgrave Ederveen¹, Gordan Lauc² and Manfred Wuhrer^{1*}

¹Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands, ²Glycoscience Research Laboratory, Genos, Zagreb, Croatia

OPEN ACCESS

Edited by:

Fabrizio Ceciliani,
Università degli Studi
di Milano, Italy

Reviewed by:

Carlos Rosales,
National Autonomous
University of Mexico, Mexico
Jan Lunemann,
University of Zurich,
Switzerland

*Correspondence:

Manfred Wuhrer
m.wuhrer@lumc.nl

Specialty section:

This article was submitted to
Comparative Immunology,
a section of the journal
Frontiers in Immunology

Received: 14 April 2017

Accepted: 09 May 2017

Published: 31 May 2017

Citation:

de Haan N, Reiding KR, Krištić J, Hipgrave Ederveen AL, Lauc G and Wuhrer M (2017) The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains. *Front. Immunol.* 8:608. doi: 10.3389/fimmu.2017.00608

N-linked glycosylation of the fragment crystallizable (Fc)-region of immunoglobulin G (IgG) is known to have a large influence on the activity of the antibody, an effect reported to be IgG subclass specific. This situation applies both to humans and mice. The mouse is often used as experimental animal model to study the effects of Fc-glycosylation on IgG effector functions, and results are not uncommonly translated back to the human situation. However, while human IgG Fc-glycosylation has been extensively characterized in both health and disease, this is not the case for mice. To characterize the glycosylation profile of murine IgG-Fc and in addition evaluate the systematic glycosylation differences between mouse strains, sexes, and IgG subclasses, we used nanoliquid chromatography mass spectrometry (nanoLC-MS/MS) to look at the subclass-specific IgG Fc-glycopeptides of male and female mice from the strains BALB/c, C57BL/6, CD-1, and Swiss Webster. The structural analysis revealed the presence of predominantly fucosylated, diantennary glycans, with varying amounts of galactosylation and α 2,6-sialylation. In addition, we report glycosylation features not previously reported in an Fc-specific way on murine IgG, including monoantennary, hybrid, and high mannose structures, as well as diantennary structures without a core fucose, with a bisecting N-acetylglucosamine, or with α 1,3-galactosylation. Pronounced differences were detected between strains and the IgG subclasses within each strain. Especially the large spread in galactosylation and sialylation levels found between both strains and subclasses may vastly influence IgG effector functions. Mouse strain-based and subclass-specific glycosylation differences should be taken into account when designing and interpreting immunological and glyco-biological mouse studies involving IgG effector functions.

Keywords: mouse, immunoglobulin G, Fc-glycosylation, N-glycans, glycopeptides, LC-MS, MALDI-TOF-MS, HILIC-UPLC-fluorescence

INTRODUCTION

Immunoglobulin G (IgG) is the most abundant antibody in human plasma and plays a crucial role in the humoral immune response (1). Various effector functions of IgG are affected by its fragment crystallizable (Fc)-glycosylation, which has shown to influence the binding of IgG-Fc to, e.g., Fc γ -receptors (Fc γ Rs) and C-type lectins (2–4). Changes in IgG Fc-glycosylation are

associated with various diseases and physiological processes. For example, galactosylation on total IgG is decreased in rheumatoid arthritis and active tuberculosis infections, and increases with pregnancy (5–7). Fucosylation on the other hand, is decreased on alloantibodies against red blood cells and platelets as well as on gp120-specific antibodies in HIV-infected patients (8–10). Modification of IgG Fc-glycosylation has also shown to be a suitable measure to improve the efficacy of therapeutic monoclonal antibodies (11).

Mice are often used as experimental animal models to study the effects of Fc-glycosylation on IgG effector functions (2, 12). Various mouse strains are established for different research areas, for example outbred strains like CD-1 or Swiss Webster are used frequently for toxicological and pharmaceutical studies (13). In addition, because CD-1 mice are efficient breeders, they are regularly used in genetic experiments (14). On the other hand, inbred strains like BALB/c and C57BL/6 are often used to study infectious diseases and cancer (15, 16).

Contrary to the human IgG Fc-glycosylation, mice predominantly express the sialic acid *N*-glycolylneuraminic acid (Neu5Gc), while humans exclusively express *N*-acetylneuraminic acid (Neu5Ac) (17). Furthermore, as IgG Fc-glycosylation is partly genetically determined (18) and partly influenced by environmental factors like exposure to immunological challenges (19), baseline Fc-glycosylation may play a role in the outcome of an immunological study, and may confound the potential translation to the human situation. Differences in total plasma *N*-glycosylation between mouse strains were demonstrated before (20). Interestingly, glycans that are for humans known to be predominantly derived from IgG (21) showed both sex and strain specific differences in the murine total plasma *N*-glycome study. For example, galactosylation of diantennary fucosylated species, which is a known immune modulator on IgGs (4), was reported to be higher for BALB/c and C57BL/6 mice, when compared with CD-1 and Swiss Webster (20).

In contrast to human IgG, which can be divided into four subclasses (IgG1–4), murine IgG only knows three subclasses (IgG1–3) (22). In addition, murine IgG2 can be split in the isotypes IgG2a, 2b and 2c, of which IgG2a and 2c are allelic variants and further sequence variants are known for IgG1 and IgG2b (23, 24). Like for human IgG, the affinity of murine IgG for the various FcγRs differs per subclass (22, 25–27). For example, defucosylation of IgG Fc-glycans has been found to improve the FcγR-mediated pro-inflammatory activity of murine IgG2b, while this is not the case for murine IgG1 (28). Despite its importance and some previous descriptions of single case murine IgG glycosylation (23), no comprehensive strain- and subclass-specific characterization was hitherto performed.

We used nanoliquid chromatography (nanoLC) coupled to electrospray ionization (ESI)-mass spectrometry (MS) to analyze glycopeptides derived from murine IgG. In this way, we were able to separate the *N*-glycosylation present on IgG1 and its sequence variant (IgG1i), as well as on IgG2b, IgG2a/c, and IgG3, and to perform a subclass-specific relative quantification thereof. The glycosylation profiling of mice from each of the commonly used strains BALB/c, C57BL/6, CD-1, and Swiss Webster revealed significant differences between both the mouse strains

and the subclasses within the strains. In addition, nanoLC-MS/MS allowed the characterization of glycan structures which, to our knowledge, were not previously reported on polyclonal murine IgG-Fc. These included high-mannose structures, hybrid structures, and structures with a bisecting *N*-acetylglucosamine (GlcNAc), without a core fucose, or with α1,3-linked galactose attached to the β-linked-galactose. Next to Neu5Gc, we detected Neu5Ac on several of the subclasses. Finally, previously reported matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-MS(/MS) (20, 29) and ultraperformance liquid chromatography (UPLC)-fluorescence (30) (Krištić et al., manuscript submitted) methods allowed to differentiate between, respectively, sialic acid linkages and antenna galactosylation in monogalactosylated species.

MATERIALS AND METHODS


Chemicals

Ultrapure deionized water was generated by the Purelab Ultra, maintained at ≥18.2 MΩ (Veolia Water Technologies Netherlands B.V., Ede, the Netherlands) and used throughout. Disodium hydrogen phosphate dihydrate (Na₂HPO₄·2H₂O), potassium dihydrogen phosphate (KH₂PO₄), NaCl, sodium dodecyl sulfate (SDS), ethanol, glacial acetic acid, and trifluoroacetic acid were purchased from Merck (Darmstadt, Germany). 1-Hydroxybenzotriazole hydrate, dimethyl sulfoxide (DMSO), ammonium bicarbonate, formic acid, Nonidet P-40 substitute (NP-40), super-DHB, NaOH, and tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin from bovine pancreas were purchased from Sigma-Aldrich (St. Louis, MO, USA), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride from Fluorochem (Hadfield, Derbyshire, UK), and HPLC SupraGradient acetonitrile (ACN) from Biosolve (Valkenswaard, the Netherlands). Recombinant peptide-*N*-glycosidase F (PNGaseF) was obtained from Roche Diagnostics (Mannheim, Germany). Phosphate-buffered saline (PBS) was made in-house, containing 5.7 g/L Na₂HPO₄·2H₂O, 0.5 g/L KH₂PO₄, and 8.5 g/L NaCl.

For specifically the UPLC-fluorescence analysis of the 2-aminobenzamide (2-AB) labeled glycans, ultra-pure deionized water was generated by the Millipore Synergy Ultrapure Water Purification System, maintained at ≥18.2 MΩ at 25°C (Merck Millipore, Billerica, MA, USA), whereas formic acid was purchased from Merck, ethanol from Carlo Erba Reagents (Val de Reuil, France) and 2-AB, DMSO, 2-picoline borane, and ACN from Sigma-Aldrich (St. Louis, MO, USA).

Samples

The disodium EDTA-plasma of 40 individual mice was purchased from BioChemed Services (Winchester, VA, USA). The mice, aged between 8 and 12 weeks, originated from the strains BALB/c, C57BL/6, CD-1, and Swiss Webster. Of each strain, five male and five female mice were included in the study. Four pooled disodium EDTA-plasma samples (one male and one female) of the same strains were purchased from Seralab (West-Sussex, UK; **Figure 1** (20)).



IgG Isolation from Murine Plasma

Murine IgG was captured from 2 μ L (for the glycopeptide workflow) or 100 μ L (for the released glycan workflow) plasma, using, respectively, 15 or 500 μ L protein G affinity beads (GE Healthcare, Uppsala, Sweden) in 100 or 1,000 μ L PBS. Proteins were allowed to interact with the beads while shaken for 1 h, after which the beads were washed three times with PBS and three times with water. IgG was eluted in 100 μ L 100 mM FA, by incubating the beads 15 min at room temperature with agitation. Eluates were dried for 2 h in a vacuum concentrator at 60°C.

Preparation of Glycopeptides

Glycopeptide analysis was performed for all 40 individual mouse samples and in addition for 6 technical replicates of the 4

pooled samples in a randomized 96-well plate format. Six blanks were included to serve as negative control. Dried IgG samples (between 3 and 5 μ g based on SDS-PAGE gel analysis; Figure S1 in Supplementary Material) were dissolved in 40 μ L 25 mM ammonium bicarbonate (pH 8) with 1 μ g TPCk-treated trypsin and incubated for 17 h at 37°C. Before nanoLC-MS analysis, all samples were diluted 20 times in ultrapure water.

Preparation of Released Glycans

Released glycan analysis was performed for the four pooled samples. The complete sample preparation was carried out in triplicate. Dried IgG samples (between 150 and 250 μ g based on SDS-PAGE-gel analysis; Figure S1 in Supplementary Material) were dissolved in 20 μ L water and 40 μ L 2% SDS and incubated for 10 min at 60°C. N-Glycans were released by adding 40 μ L

release mixture (2 mU PNGase F and 2% NP-40 in 2.5× PBS) and incubating for 17 h at 37°C.

Prior to MALDI-TOF-MS analysis, sialic acids were stabilized in a linkage-specific way by ethyl esterification (29). Two microliters of the released glycans were added to 20 µL derivatization reagent (250 mM 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide and 250 mM 1-hydroxybenzotriazole in ethanol) and incubated for 1 h at 37°C. Twenty microliters of ACN were added and derivatized glycans were enriched by cotton hydrophilic-interaction liquid chromatography (HILIC)–solid-phase extraction (SPE) as described before and eluted in 10 µL water (29, 31).

Prior to UPLC analysis, the released glycans were labeled at the reducing end with 2-AB. Ninety microliters of the released glycans was dried and reconstituted in 50 µL of water. The labeling mixture was freshly prepared by dissolving 19.2 mg/mL 2-AB and 44.8 mg/mL 2-picoline borane in DMSO and glacial acetic acid (70:30, v/v). Twenty-five microliters of labeling mixture were added to each sample in a 96-well plate format, and the plate was sealed using adhesive tape. Samples were mixed by a 10-min shaking step, followed by 2 h incubation at 65°C. After incubation, samples were left to cool down to room temperature for 30 min. The samples (in a volume of 75 µL) were mixed with 700 µL of cold 100% ACN. Free label and reducing agent were removed from the samples using HILIC-SPE on a 0.2 µm GHP filter plate (Pall Corporation, Ann Arbor, MI, USA). Solvent was removed by a vacuum manifold (Millipore Corporation, Billerica, MA, USA). All wells were prewashed using 200 µL of 70% ethanol, followed by 200 µL of water and equilibrated with 200 µL of cold 96% ACN. The samples were loaded onto the GHP filter plate and incubated for 2 min before the vacuum application. The wells were subsequently washed 5 times using 200 µL of cold 96% ACN. The last washing step was followed by centrifugation at 1,000 rpm for 5 min. Glycans were eluted two times with 90 µL of water after 15 min of shaking at room temperature followed by centrifugation at 1,000 rpm for 5 min. The combined eluates were stored at –20°C until usage.

Nanoliquid Chromatography Mass Spectrometry of Glycopeptides

The 20 times diluted tryptic digests of the IgG samples were separated with an Ultimate 3000 RSLCnano system (Dionex/Thermo Scientific, Breda, the Netherlands) equipped with an Acclaim PepMap 100 trap column (100 µm × 20 mm, particle size 5 µm, Dionex/Thermo Scientific) and an Acclaim PepMap RSLC C18 nano-column (75 µm × 150 mm, particle size 2 µm, Dionex/Thermo Scientific). Two microliters of sample were injected and separated with a gradient from 97% solvent A (0.1% formic acid in water) and 3% solvent B (95% ACN) to 27% solvent B over 15 min, with a flow rate of 700 nL/min. The nanoLC was coupled to a maXis HD quadrupole time-of-flight-MS (q-TOF-MS; Bruker Daltonics) via an ESI interface, equipped with the CaptiveSpray and nanoBooster technologies (Bruker Daltonics), using ACN-doped nebulizing gas. Profile spectra were recorded in *m/z* range 550 to 1,800 with a frequency of 1 Hz. The collision energy was 5 eV, the transfer time 130 µs, and the pre-pulse storage

10 µs. The total analysis time per sample was 19 min. The nanoLC system and the q-TOF-MS were operated under Chromeleon Client version 6.8 and otofControl version 4.0.15, respectively. For a closer examination of the glycoforms present, nanoLC-MS/MS was performed on a pooled sample of the undiluted digests of all 40 individual mouse samples. Five microliters of the pooled sample were injected and all putative glycopeptide peaks were selected for MS/MS fragmentation analysis by collision-induced dissociation.

Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of Released Glycans

MALDI-TOF(/TOF)-MS(/MS) analysis was performed on an UltrafleXtreme (Bruker Daltonics) operated under flexControl 3.3 (Build 108; Bruker Daltonics). One microliter of the enriched ethyl-esterified glycans was spotted on a MALDI target (MTP AnchorChip 800/384 TF; Bruker Daltonics) together with 1 µL 5 mg/mL super-DHB in 50% ACN and 1 mM NaOH. The spots were dried by air at room temperature. For each spot, a mass spectrum was recorded from *m/z* 1,000 to 3,000, combining 10,000 shots in a random walk pattern at 1,000 Hz and 100 shots per raster spot. Prior to the analysis of the samples, the instrument was calibrated using peptide calibration standard (Bruker Daltonics). MALDI-TOF/TOF-MS/MS of the most abundant peaks was performed by laser-induced dissociation.

Ultraperformance Liquid Chromatography with Fluorescence Detection of Released Glycans

Fluorescently labeled *N*-glycans were separated by HILIC on a Waters Acquity UPLC instrument (Milford, MA, USA) consisting of a quaternary solvent manager, sample manager and a FLR fluorescence detector set with excitation and emission wavelengths of 250 and 428 nm, respectively. The instrument was under the control of Empower 3 software, build 3471 (Waters, Milford, MA, USA). The UPLC system was equipped with a Waters BEH Glycan chromatography column (100 mm × 2.1 mm i.d., 1.7 µm BEH particles). Forty microliters of (80% ACN:20% water) sample were injected and separated with a gradient of 75% solvent B (100% ACN; solvent A:100 mM ammonium formate pH 4.4) to 62% solvent B over 27 min, with a flow of 0.4 mL/min. Solvent B was maintained at 62% for an additional 5 min. Samples were maintained at 10°C before injection, and the separation temperature was 60°C. The system was calibrated using an external standard of hydrolyzed and 2-AB-labeled glucose oligomers from which the retention times for the individual glycans were converted to glucose units.

Data Processing

For automated relative quantification of the glycopeptides by LaCyTools (version 1.0.1, build 8) (32), the nanoLC-MS files were converted to mzXML files. Chromatograms were aligned based on at least six glycopeptide signals with a signal-to-noise ratio (S/N) above nine, covering the full elution range of the glycopeptides

(412–716 s; Table S1 in Supplementary Material). Targeted peak integration was performed on doubly, triply, and quadruply charged species. Twelve chromatographic glycopeptide clusters were defined, one per IgG subclass (IgG1, IgG1i, total IgG2, and IgG3), and within each subclass one per degree of sialylation (0, 1, or 2 sialic acids; Table S2A and Figure S2 in Supplementary Material). Sum spectra were created for these clusters and signals were integrated to include at least 85% of the theoretical isotopic pattern. The actual presence of a glycopeptide was assessed based on the mass accuracy (between -20 and 20 ppm), the deviation from the theoretical isotopic pattern (IPQ; below 25%), and the S/N (above nine) of an integrated signal. Analytes were included for all samples when present in at least 50% of the spectra of one biological group (vendor, strain, and sex). For the glycopeptides that passed analyte curation for total IgG2, new extraction clusters were defined to separate IgG2b glycoforms from IgG2a/c glycoforms (two clusters per analyte; Table S2B in Supplementary Material). Again, glycoforms were included when meeting the requirements described above. Glycopeptide signals were corrected for the actual percentage of isotopic pattern integrated, the included charge states were summed per analyte and absolute values were normalized to the total signal intensity per IgG subclass. For the in-depth analysis of compositional features, derived traits were calculated (Table S3 in Supplementary Material; (20, 33)).

For automated relative quantification of the released glycans analyzed by MALDI-TOF-MS, using MassyTools (version 0.1.8.1.) (34), the MALDI-TOF-MS files were converted to text files. Spectra were calibrated based on at least six glycan signals with a S/N above nine, covering the full m/z range of the glycans (Table S4 in Supplementary Material). Targeted peak integration was performed for an extensive visually-determined list of glycans, including at least 95% of the theoretical isotopic pattern. The actual presence of a glycan was assessed based on the mass accuracy (between -20 and 20 ppm), the IPQ (below 25%), and the S/N (above nine) of an integrated signal. Analytes were included for all samples when present in at least two-thirds of one of the technical triplicates. Glycan signals were normalized to the total signal intensity.

The chromatographic glycan peaks resulting from the UPLC-fluorescence analysis were integrated using an automatic processing method with the “traditional integration algorithm” after which each chromatogram was manually corrected to maintain the same intervals of integration for all samples. In this way, all chromatograms were separated into 27 peaks and the amount of glycans in each peak was expressed as a percentage of the total integrated area. Assignment of the glycans structures in all major UPLC peaks was performed as described elsewhere (Krištić et al., manuscript submitted).

Data Analysis

Statistical analysis of the glycopeptide data was performed using R 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and RStudio 0.98.1091 (RStudio, Inc.). Because of the small sample sizes (between 5 and 40 cases) and the skewing in the distribution of some of the glycosylation traits, non-parametric Mann–Whitney U tests were performed to assess sex-, strain-,

and subclass-specific glycosylation differences. Multiple testing was accounted for by Bonferroni-correction of the significance threshold (α) per biological question. Differences between the sexes were assessed based on the combined strains (47 tests; $\alpha = 0.05/47 = 1.1 \times 10^{-3}$; Table S5 in Supplementary Material), as well as for the individual strains (168 tests; $\alpha = 3.0 \times 10^{-4}$; Table S5 in Supplementary Material). Subsequently, the sexes were combined to compare the glycosylation between the different strains (222 tests; $\alpha = 2.3 \times 10^{-4}$; Table S6 in Supplementary Material), between the different subclasses of the combined strains (87 tests; $\alpha = 5.7 \times 10^{-4}$; Table S7 in Supplementary Material), and between the different subclasses of the individual strains (87 tests each; $\alpha = 5.7 \times 10^{-4}$; Table S8 in Supplementary Material).

RESULTS

Glycoform Characterization

The IgG Fc-glycosylation of 40 individual mice of four strains (BALB/c, C57BL/6, CD-1, and Swiss Webster) and both sexes (five mice per strain per sex) was analyzed by nanoLC-MS(/MS) of tryptic glycopeptides in a subclass-specific manner. In addition, the strain-specific IgG Fc-glycosylation was studied for four plasma pools of one male and one female mouse per strain (Figures 1 and 2A). A total of 32 different glycan compositions was detected on the combination of IgG subclasses, whereof 27 on IgG1, 22 on IgG1i, 24 on IgG2b, 25 on IgG2a/c, and 21 on IgG3, showing a vast overlap of the glycoforms present per subclass (Table 1; Figures S2–S5 in Supplementary Material). In addition to the nanoLC-MS(/MS) analysis of glycopeptides, the total IgG glycans of the four pooled samples (one of each strain) were enzymatically released and analyzed by both MALDI-TOF(/TOF)-MS(/MS) after sialic acid linkage-specific derivatization and UPLC-fluorescence after 2-AB labeling. The latter two methods allowed the distinction between α 2,3- and α 2,6-linked sialic acids, and α 1,3- and α 1,6-antenna galactosylation, respectively (Figures 2B,C).

For all subclasses and in all mice the most abundant glycoforms (approximately 90% of the total area) included diantennary glycans with 0, 1, or 2 galactoses, a core fucose, and 0, 1, or 2 α 2,6-linked sialic acids, all in agreement with literature (17, 23). In all samples, the sialic acids proved to be mainly *N*-glycolylneuraminic acid (Neu5Gc) (17, 23), with only the IgG2 isotypes showing the additional presence of *N*-acetylneuraminic acid (Neu5Ac) (IgG2a/b/c glycoform H5N4F1G1S1; H: hexose, N: *N*-acetylhexosamine, F: fucose, G: Neu5Gc, S: Neu5Ac; Table S9 in Supplementary Material). The presence of these minor amounts of Neu5Ac was also registered by MALDI-TOF/TOF-MS/MS analysis (H5N4F1E1Ge1; E: α 2,6-linked Neu5Ac, Ge: α 2,6-linked Neu5Gc; Table S9 in Supplementary Material). In addition to the α 2,6-linked Neu5Gc, the MALDI-TOF-MS method showed α 2,3-linked Neu5Gc to be present in the form of H5N4F1G1I, H5N4G1I1Ge1, and H5N4F1G1I1Ge1 (GI: α 2,3-linked Neu5Gc; Table S9 in Supplementary Material).

Next to the fucosylated diantennary glycans described above, also variants without core fucose, with bisecting GlcNAc or with




FIGURE 2 | Glycoforms detected by the three synergistic analysis methods. Representative data and analytes detected in the analysis of the pooled CD-1 sample, showing (A) immunoglobulin G1 (IgG1) fragment crystallizable (Fc)-glycopeptides analyzed by nanoliquid chromatography mass spectrometry (nanoLC-MS), (B) the 20 most abundant released glycans of total IgG analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)-MS after linkage-specific sialic acid derivatization, and (C) released glycans of total IgG analyzed by ultraperformance liquid chromatography (UPLC)-fluorescence after 2-AB labeling. Except for the sialic acid linkage in the MALDI-TOF-MS analysis (B), and the antenna galactosylation in the UPLC-fluorescence analysis (C), the monosaccharide linkages were not determined. The proposed glycan structures are based on fragmentation and literature (17, 23, 35, 36).

α 1,3-galactosylation on the β -linked-galactoses were detected on mouse IgG-Fc. Bisection was confirmed by nanoLC-MS/MS analysis of the H4N5F1G1 glycoform on IgG1 (Table S9 in Supplementary Material) and in accordance with literature (17, 35). The presence of an extra hexose on diantennary, digalactosylated structures was indicated by nanoLC-MS/MS analysis of the glycan composition H6N4F1G1 on IgG1 (Table S9 in Supplementary Material). In line with literature, this structure as well as H6N4F1 and H6N4G1, were assigned to diantennary structures that

carry an α 1,3-galactose on one of their antennae (Table S9 in Supplementary Material) (36–38).

Besides diantennary glycans, also monoantennary, high mannose and hybrid structures were detected on the IgG Fc-glycopeptides. While monoantennary glycans were reported before on mouse IgG (17), high mannose and hybrid structures were not. Both H5N2 and H6N2 were detected at the glycopeptides level (Table S9 in Supplementary Material), H8N2 was additionally observed in the MALDI-TOF-MS analysis (Table S9

TABLE 1 | Detected glycoforms per IgG subclass by nanoLC-MS.

Glycoform composition ^a	Depiction ^b	IgG1 ^c	IgG1i	IgG2b	IgG2a/c	IgG3
H2N3F1		x	x	x	x	
H5N2		x	x			x
H3N3F1		x	x	x	x	x
H3N4		x	x			x
H6N2		x				
H4N3F1		x	x	x	x	x
H3N4F1		x	x	x	x	x
H4N4		x	x	x	x	x
H5N3F1			x	x	x	
H4N4F1		x	x	x	x	x
H5N4		x		x	x	x
H3N5F1		x	x		x	
H4N5						x
H4N3F1G1		x	x	x	x	x
H4N4G1			x			
H5N4F1		x	x	x	x	x
H4N5F1		x		x	x	x
H5N3F1G1		x	x	x	x	
H4N4F1G1		x	x	x	x	x
H5N4G1		x	x	x	x	x
H6N4F1		x	x	x	x	x
H5N5F1		x				x
H6N3F1G1		x	x	x	x	x
H5N4F1G1		x	x	x	x	x
H6N4G1		x				
H4N5F1G1		x	x	x	x	x
H5N4G2				x	x	
H6N4F1G1		x	x	x	x	x
H5N5F1G1		x		x	x	
H5N4F1G1S1				x	x	
H5N4F1G2		x	x	x	x	x
H5N5F1G2		x		x	x	

^aH: hexose, N: N-acetylhexosamine, F: fucose, G: N-glycolylneuraminic acid, S: N-acetylneuraminic acid.

^bSymbols used: green circle: mannose, yellow circle: galactose, blue square: N-acetylglucosamine, red triangle: fucose, white diamond: N-glycolylneuraminic acid, pink diamond: N-acetylneuraminic acid. The proposed glycan structures are based on fragmentation and literature (17, 23, 35, 36). See also Table S9 in Supplementary Material.

^cPeptide sequence of IgG1: EEQFNSTFR, IgG1i: EEQINSTFR, IgG2b: EDYNSTIR, IgG2a/c: EDYNSTLR, IgG3: EAQYNSTFR.

in Supplementary Material). The presence of hybrid structures was confirmed by nanoLC-MS/MS of H6N3F1G1 on IgG1 (Table S9 in Supplementary Material).

Sex- and Strain-Specific IgG Fc-Glycosylation

Based on the glycopeptide analysis of the 40 individual mice, it was shown that the two isotypes of IgG1, i.e., IgG1 (UniProt

TABLE 2 | Derived glycosylation traits.

Derived trait	Depiction ^a	Description
Total		Sum of all glycans
M		Fraction of high mannose glycans
Hy		Fraction of hybrid glycans
A1		Fraction of N3 glycans (non-hybrid)
A2aF		Afucosylation of diantennary glycans
A2B		Bisection of diantennary glycans
A2G		Galactosylation per antenna of diantennary glycans
A2Ga		α1,3-Galactosylation per antenna of diantennary glycans
A2GGa		α1,3-Galactosylation per β-galactose of diantennary glycans
A2S		Sialylation per antenna of diantennary glycans
A2GS		Sialylation per β-galactose of diantennary glycans
S2Sa		Fraction of Neu5Ac on disialylated, diantennary glycans

^aThe depictions of the derived traits show the minimally required composition to contribute to a trait. Symbols used: green circle: mannose, yellow circle: galactose, blue square: N-acetylglucosamine, red triangle: fucose, white diamond: N-glycolylneuraminic acid, pink diamond: N-acetylneuraminic acid. For exact calculations per IgG subclass see Table S3 in Supplementary Material.

entry P01868) and IgG1i (A0A075B5P4), were simultaneously present in four of the CD-1 mice and five of the Swiss Webster mice, while the others expressed exclusively one of the two forms. In addition, BALB/c and C57BL/6 showed solely the respective presence of IgG1 and IgG1i. IgG2b (P01867/A0A075B5P3), IgG3 (P03987), IgG2a (P01863/P01864) and/or IgG2c (A0A0A6YY53) glycopeptides were observed in all mice, although no distinction could be made between the IgG2a and IgG2c isotypes as they resulted in the same tryptic glycopeptides (Table 1; Table S10 in Supplementary Material).

For the relative quantification of the glycoforms, absolute intensities were normalized per subclass. In addition, derived traits were calculated based on compositional features (Table 2; Table S3 in Supplementary Material). The derived traits per IgG subclass, such as overall galactosylation and sialylation, were compared between the four strains using Mann–Whitney *U* tests. As no difference was found between sexes for any of the testing groups, male and female mice were pooled for all subsequent analyses (Table S5 in Supplementary Material).

Many glycosylation traits showed to differ between strains, one of the most pronounced differences being the relative abundance of bisecting GlcNAc on diantennaries (A2B). A2B was low throughout, but clearly higher in BALB/c and C57BL/6 (e.g., IgG2b medians of 1.0 and 0.7%) than in CD-1 and Swiss Webster (0.3 and 0.2%; for statistical test outcomes see Table 3, Table S6

TABLE 3 | Fold differences in the derived glycosylation traits between the strains.

Derived trait ^a	C57BL/6/BALB/c ^b	CD-1/BALB/c	SW/BALB/c	CD-1/C57BL/6	SW/C57BL/6	CD-1/SW
IgG1						
A2B	n.d.	0.22	0.27	n.d.	n.d.	1.22
A2GS	n.d.	0.68	0.75	n.d.	n.d.	1.10
IgG2b						
Hy	0.56	0.29	0.20	0.53	0.36	0.69
A1	0.56	1.33	1.08	2.36	1.92	0.82
A2aF	0.80	1.09	0.96	1.35	1.20	0.88
A2B	0.74	0.29	0.24	0.39	0.33	0.84
A2S	1.14	0.75	0.82	0.66	0.72	1.09
A2GS	1.10	0.80	0.87	0.73	0.79	1.08
S2Sa	0.36	0.55	0.37	1.53	1.03	0.68
IgG2a/c						
Hy	0.98	0.23	0.19	0.23	0.19	0.83
A2aF	1.27	0.71	0.75	0.56	0.59	1.05
A2B	1.92	0.23	0.20	0.12	0.10	0.87
A2G	1.39	1.02	1.06	0.74	0.76	1.04
A2Ga	1.93	0.98	0.98	0.51	0.51	1.00
A2S	2.33	1.16	1.46	0.50	0.63	1.27
A2GS	1.65	1.09	1.26	0.66	0.76	1.15
IgG3						
A1	1.18	0.72	0.73	0.61	0.62	1.01
A2B	2.63	1.19	1.36	0.45	0.52	1.14
A2G	1.10	0.81	0.79	0.74	0.72	0.97
A2S	1.14	0.73	0.77	0.64	0.68	1.06

^aFor an explanation of the derived traits see **Table 2** and **Table S3** in Supplementary Material.

^bPresented values indicate the fold difference between the group medians of strain A/strain B (indicated above each column). Values in bold: statistically significant, n.d.: not determined.

in Supplementary Material, and **Figure 3A**). This difference was detected for all IgG subclasses except IgG3, where the A2B was found to be similarly low for BALB/c (IgG3 BALB/c: 1.9%, C57BL/6: 5.0%, CD-1: 2.3%, and SW: 2.6%).

All strains had low levels of afucosylated glycans, with BALB/c and C57BL/6 having a slightly higher relative abundance of afucosylated diantennaries (A2aF) on IgG2a/c (1.0 and 1.3%) than CD-1 (0.7%; **Table S6** and **Figure S6** in Supplementary Material). This trend appeared similar for IgG1, IgG1i, and IgG3 (**Figure 3B**; **Table S6** and **Figure S6** in Supplementary Material).

Differences in antenna galactosylation (A2G) between the four strains were specifically observed for IgG2a/c and IgG3. On IgG2a/c, galactosylation was high for C57BL/6 (61%), when compared with all other strains (e.g., BALB/c: 44%; **Table S6** and **Figure S6** in Supplementary Material). On IgG3, high galactosylation was seen in BALB/c and C57BL/6 (38 and 42%), when compared with CD-1 and Swiss Webster (31 and 30%; **Figure 3C**). UPLC-fluorescence analysis showed furthermore the galactose on the monogalactosylated species to be between 78 and 85% on the α 1,6-antenna for H4N4F1 and between 51 and 62% on the α 1,6-antenna for H4N4F1G1 (**Figure S7** in Supplementary Material). Sialylation (A2S) followed the same behavior as the galactosylation on IgG3 and IgG2a/c, showing IgG3 A2S to be higher for BALB/c and C57BL/6 (9.2 and 11%) than for CD-1 (6.7%), and IgG2a/c A2S to be higher for C57BL/6 (18%) than for all other strains (e.g., BALB/c: 7.5%; **Table S6** and **Figure S6**

in Supplementary Material). In addition A2S on IgG2b was lower for CD-1 (13%) than for C57BL/6 (20%; **Figure 3D**).

Finally, strain-specific differences were found for the relative abundance of hybrid structures (Hy) on the two isotypes of IgG2, namely a high degree of hybrid structures on IgG2a/c for BALB/c and C57BL/6 (both 0.8%) when compared with CD-1 and Swiss Webster (both 0.2%), and on IgG2b for BALB/c (0.6%) when compared with CD-1 and Swiss Webster (0.2 and 0.1%; **Table S6** and **Figure S6** in Supplementary Material).

No significant differences were found between the strains for the glycosylation traits on IgG1i, likely due to a reduced statistical power as IgG1i was only present in five of the studied CD-1 and six of the studied Swiss Webster mice. However, the IgG1i derived glycosylation traits followed the trends observed for the IgG2 and IgG3 traits between the strains (**Table 3**; **Table S6** in Supplementary Material). None of the derived glycosylation traits appeared to be different between CD-1 and Swiss Webster.

Subclass-Specific Glycosylation

Glycosylation differences between subclasses were assessed for the 40 mice of the combined strains using the Mann–Whitney *U* test (**Table 4**; **Table S7** in Supplementary Material). In addition, all glycosylation differences between the subclasses were confirmed by the analysis of the four pooled plasma samples (**Figure S8** in Supplementary Material).

One of the most noticeable differences between subclasses was the level of A2G, which proved highest on IgG2b (median 60%), followed by IgG2a/c (47%), IgG3 (35%), IgG1 (34%), and IgG1i (26%; **Figure 4A**). A2S showed a similar pattern, being highest on IgG2b (17%) followed by IgG1 (11%), IgG2a/c (9.6%) and IgG3 (8.4%), and IgG1i (5.7%; **Figure 4B**). Also the sialylation per galactose (A2GS) was not the same for all subclasses, namely higher on IgG1 (31%) and IgG2b (28%) when compared with IgG3 (24%) and IgG2a/c (21%; **Figure 4C**). This effect could specifically be attributed to BALB/c, which showed low IgG2a/c A2GS (18%) and high IgG1 A2GS (40%; **Table S8** in Supplementary Material).

For the overall sample set, the abundance of A2aF was higher for IgG1 (2.0%), IgG1i (1.7%), and IgG3 (1.5%) than for IgG2a/c (0.9%; **Figure 4D**). Furthermore, A2B, was consistently low on both IgG2 isotypes (IgG2b: 0.5%, IgG2a/c: 0.7%), as well as on IgG1i (1.0%), compared to IgG1 (2.7%) and IgG3 (2.6%; **Figure 4E**). The presence of α 1,3-galactosylation on diantennaries (A2Ga) was relatively constant over all subclasses (IgG2a/c: 0.7%, IgG2b: 0.8%, IgG3: 0.9%, and IgG1i: 1.2%), except on IgG1 (0.4%), on which it was significantly lower than on all others (**Figure 4F**). This effect was even more pronounced when studied for BALB/c specifically (IgG1: 0.4% and, e.g., IgG2b: 0.9%; **Table S8** in Supplementary Material).

DISCUSSION

In this research we present, to our knowledge, the most in-depth characterization of mouse IgG Fc-glycosylation conducted to date. Next to thorough IgG glycoform characterization, we provide the subclass-specific comparison of the IgG Fc-glycosylation




FIGURE 3 | Differences in the relative abundances of glycosylation traits between strains. Relative abundances of the derived glycosylation traits (A) bisectation (A2B), (B) afucosylation (A2aF), (C) galactosylation (A2G), and (D) sialylation (A2S) on immunoglobulin G2b (IgG2b) and IgG3 for the four different mouse strains: BALB/c, C57BL/6, CD-1, and Swiss Webster (SW). Significant differences between strains are indicated by black lines above the boxes. Boxes represent the interquartile range (IQR) and median value, whiskers represent the first and the third quartiles, respectively, minus or plus 1.5 times the IQR.

TABLE 4 | Fold differences in the derived glycosylation traits between the IgG subclasses.

Derived trait ^a	IgG1i/ IgG1 ^b	IgG2b/ IgG1	IgG2a/c/ IgG1	IgG3/ IgG1	IgG2b/ IgG1i	IgG2a/c/ IgG1i	IgG3/ IgG1i	IgG2a/c/ IgG2b	IgG3/ IgG2b	IgG3/ IgG2a/c
Hy	1.09	0.35	0.42	n.d.	0.32	0.38	n.d.	1.18	n.d.	n.d.
A1	2.66	0.40	0.82	1.89	0.15	0.31	0.71	2.05	4.73	2.30
A2aF	0.87	0.39	0.47	0.77	0.45	0.54	0.89	1.20	1.97	1.64
A2B	0.39	0.20	0.24	0.98	0.51	0.62	2.51	1.22	4.95	4.04
A2G	0.76	1.77	1.38	1.04	2.33	1.82	1.37	0.78	0.59	0.75
A2Ga	3.04	2.13	1.70	2.37	0.70	0.56	0.78	0.80	1.11	1.39
A2GGa	3.33	1.26	1.19	2.05	0.38	0.36	0.62	0.94	1.63	1.73
A2S	0.53	1.53	0.89	0.78	2.90	1.67	1.46	0.58	0.51	0.88
A2GS	0.83	0.91	0.68	0.79	1.10	0.82	0.95	0.75	0.87	1.16

^aFor an explanation of the derived traits see Table 2 and Table S3 in Supplementary Material.

^bPresented values indicate the fold difference between the group medians of IgG A/IgG B (indicated above each column). Values in bold: statistically significant, n.d.: not determined.

of several commonly used mouse strains. Previous studies into the characterization of mouse IgG glycosylation made use of enzymatically released glycans from isolated IgG, losing both Fc- and subclass-specificity (17, 35). Here, IgG Fc-glycosylation profiling was achieved in a subclass-specific way by analyzing

tryptic glycopeptides by nanoLC-MS(/MS). The methodology was reported before, but never applied to multiple mice of different strains and sexes (23). We included in our study five male and five female mice of the commonly used strains BALB/c, C57BL/6, CD-1, and Swiss Webster. On top of the nanoLC-




FIGURE 4 | Differences in the relative abundances of glycosylation traits between the immunoglobulin G (IgG) subclasses. Relative abundances of the derived glycosylation traits **(A)** galactosylation (A2G), **(B)** sialylation (A2S), **(C)** sialylation per galactose (A2GS), **(D)** afucosylation (A2aF), **(E)** bisection (A2B), and **(F)** α 1,3-galactosylation (A2Ga) on the different IgG subclasses studied for the 40 individual mice of all strains. Significant differences between subclasses are indicated by black lines above the boxes. Box and whisker plots as described in **Figure 3**.

MS(/MS) method, we used two additional techniques for the in-depth characterization of the released IgG *N*-glycans, namely MALDI-TOF(/TOF)-MS(/MS) and UPLC-fluorescence.

Detected Glycoforms

Consistent with literature, our methods revealed the presence of mainly fucosylated, diantennary glycans with zero to two galactoses and sialic acids (17, 23, 35). The sialic acids were predominantly found as α 2,6-Neu5Gc, but the presence of minor amounts of α 2,6-Neu5Ac was detected as well. As CMP-Neu5Ac is the precursor for the CMP-Neu5Gc synthesis the presence of this substrate may be assumed in murine plasma cells (39). Next to α 2,6-Neu5Gc, also α 2,3-Neu5Gc was present in low abundances, although this feature could not be assigned to the Fc-portion specifically, as the sialic acid linkage-differentiation was only achieved on the released glycan level (**Figure 1**). Furthermore, on the released glycan level, we performed with UPLC-fluorescence a relative quantification of α 1,6-antenna galactosylation, when compared with the α 1,3-antenna galactosylation for monogalactosylated glycans. The α 1,6-antenna showed to be preferably galactosylated, consistent with literature on both human and mouse IgG glycosylation (17, 30). Interestingly, the α 1,6-antenna preference was lower for

the sialylated H4N4F1G1 when compared with non-sialylated H4N4F1, which might be explained by steric constraints of the α 1,6-antenna availability for processing as soon as it is galactosylated (40). On the other hand, this ratio might be influenced by varying distributions of these glycoforms over the subclasses, in combination with unequal IgG subclass abundances.

The presence of afucosylated diantennaries, as well as that of a bisecting GlcNAc on the diantennaries, is well-known for human IgG-Fc (30, 33, 41, 42), but has not yet been reported in an Fc-specific way for mouse IgG before (23). Interestingly, we identified both afucosylation and bisection on all IgG subclasses. The enzyme catalyzing the addition of a bisecting GlcNAc to the β -mannose in the *N*-glycan core, GlcNAc-transferase III, was reported to be expressed in human B lymphocytes (43) and murine brain and kidney tissues (44, 45), making the bisection on mouse IgG-Fc not unimaginable. In addition, both bisection and afucosylation were reported before for glycans released from isolated murine IgG (17).

Whereas α 1,3-galactosylation was previously only reported on monoclonal IgG produced in the mouse cell-lines SP2/0 and J558L (36, 37), we here demonstrate its presence on polyclonal murine IgG-Fc. α 1,3-Galactosylation is immunogenic in humans, in which the α 1,3-galactosyltransferase is not functionally

expressed (46). For mice, α 1,3-galactosylation is a known glycosylation feature (38).

Next to the diantennary glycan variants described, also high-mannose, hybrid and monoantennary structures were identified specifically on the mouse Fc. Where monoantennary glycans were already reported on murine IgG before, both high mannoses and hybrids were not (17). These glycoforms can be expected as they are precursors of the complex diantennary glycans (47).

Strain and Subclass Differences

Interestingly, not all IgG subclasses were detected equivalently between the mouse strains and even individuals. We revealed the presence of IgG2b and IgG3 in all mice studied. However, the inbred BALB/c and C57BL/6 mice respectively expressed only IgG1 or IgG1i, while several individuals of outbred CD-1 and Swiss Webster mice showed both isotypes at the same time, which would suggest IgG1 and IgG1i to be allelic variants. This situation was prior reported for IgG2a and IgG2c showing IgG2a to be exclusively present in BALB/c and IgG2c in C57BL/6 (23, 24). However, we were not able to assess this, as the tryptic digestion of IgG2a and IgG2c resulted in the same glycopeptides which were detected in all mice.

When comparing the glycosylation traits between the strains, we observed galactosylation and sialylation to have a lower variation between the individual mice of BALB/c and C57BL/6, when compared with CD-1 and Swiss Webster. As outbred strains are expected to have a wider genetic background than inbred strains, this suggests that there is a strong genetic influence on IgG Fc-glycosylation (13, 14, 48). Next to the genetics, also environmental factors might play a role in the differences between the strains, like exposure to pathogens and health status. For example, the high levels of IgG1 bisection and afucosylation and low levels of IgG1 galactosylation in BALB/c mice, when compared with the other strains in this study, may well represent a more proinflammatory phenotype (28, 49, 50).

The difference in variation between the mouse strains was observed before in the analysis of the murine total plasma *N*-glycome (20). Diantennary, fucosylated glycans in the total plasma *N*-glycome, for healthy humans known to be almost exclusively derived from IgG (21), showed a larger biological variation in the strains CD-1 and Swiss Webster when compared with C57BL/6 and BALB/c. To the contrary, whereas for the total IgG glycans in the total plasma *N*-glycome a clear difference was observed between male and female CD-1 and Swiss Webster mice, this was not the case in the current IgG subclass specific glycopeptide analysis. This might be explained by an interplay between, on the one hand, IgG subclass abundances between the sexes, and on the other hand, glycosylation differences between the IgG subclasses. In addition, hitherto unidentified glycoproteins, other than IgG, that show a pronounced sex specificity may overlap with the IgG glycans in the total plasma *N*-glycome. Other sex-related glycosylation differences observed in the total plasma *N*-glycome study are in glycans that are derived from proteins other than IgG and might indeed have a sex-influenced glycosylation pattern.

Both galactosylation and sialylation of IgG Fc-glycans are established traits involved in the anti-inflammatory activity of

IgG (4, 51, 52). On the one hand, sialylation has been reported to dampen immune responses in an antigen-independent way by binding SIGN-R1 (mouse) and DC-SIGN (human) (3, 53), is suggested to be involved in the inhibition of B-cell activation in mice (54) and is in addition able to decrease complement-mediated cytotoxicity *via* C1q binding (55). An increased galactosylation, on the other hand, causes improved binding of mouse IgG1 to the Fc γ RIIB and subsequent downregulation of proinflammatory activities (4). Of note, the latter phenomenon is observed for IgG1, but not for IgG2a, emphasizing the differences between the IgG subclasses (4).

Another trait known to influence antibody activity in both humans and mice is afucosylation. An increased afucosylation on human IgG1 and murine IgG2a and IgG2b is known to result in an improved binding to specific Fc γ Rs (Fc γ RIII in humans and Fc γ RIIB and Fc γ RIV in mice) and thereby increasing antibody-dependent cellular cytotoxicity (ADCC) (28, 56). Similar to the galactosylation described above, it is relevant to study afucosylation in a subclass-specific way to predict its effect. As IgG subclasses have varying binding affinities for the Fc γ Rs, differential afucosylation can alter the ratio between activating and inhibiting Fc γ R stimulation. For example, the *in vivo* effect of mouse IgG2b afucosylation on ADCC is larger than that of IgG2a (28).

Translation of Murine IgG-Fc Glycosylation to the Human System

In terms of glycan structures identified, our mouse data match the glycoforms reported on human IgG-Fc to a large extent, but several pronounced and relevant differences were also observed. One example of this is the earlier-reported difference between the most abundant sialic acid structure, namely Neu5Gc in the mouse and Neu5Ac in man (12, 17, 23, 35), and another is the alternative termination of murine glycans by α 1,3-galactosylation instead of (or next to) sialylation. Both factors are important in assessing the suitability of mice for immunological studies, as they might change the interaction between IgG-Fc and effector proteins. For example, it was shown that not the mouse sialic acid-binding Ig-like lectin CD22, but only the human CD22 is able to bind Neu5Ac on intravenous immunoglobulin (12, 57).

Of importance for interpretation of the data is that mouse IgG-subclass nomenclature does not match that of humans, human IgG1 and IgG3 are often directed against protein antigens, while for mice this is the case for IgG2a and IgG2b (26, 58). In addition, human IgG4 is similar to mouse IgG1 in its involvement in responses to allergens and mast-cell binding, and human IgG2 is similar to mouse IgG3 in the recognition of carbohydrate antigens (26, 58, 59). Furthermore, the affinity for Fc γ Rs is not consistent between mouse and human IgG subclasses, as human IgG1 has a broad affinity for all Fc γ Rs, while for the mouse this is achieved by IgG2a and IgG2b (60, 61). In addition, the inhibitory Fc γ RIIB binds in mice to IgG1, 2a, and 2b, while in human it binds to IgG1, 3, and 4 (22).

The mice we studied were aged between eight and twelve weeks and considered young adults (62). Comparing their IgG2b and IgG2a/c galactosylation to that found previously on IgG1 in healthy human between 20 and 40 years, similar levels

were observed (63). The other murine IgG subclasses showed considerably lower levels of galactosylation. The murine IgG2a/c and 2b sialylation, on the other hand, was found to be high in mice, when compared with overall human IgG Fc-sialylation. In addition, the overall bisection and afucosylation were lower on all subclasses in mice than in humans (30, 63). This latter finding might be related to the infrequent immunological challenges lab mice experience. The same phenomenon was observed before in very young children (aged between 0.3 and 4 years), showing low levels of afucosylated IgGs, which increased with age (and likely immunological challenges) (33). In addition, high levels of afucosylated antibodies were observed before in human on antigen-specific antibodies against, amongst others, HIV gp120, human platelet antigen and red blood cells (8–10). Interestingly, the mice showed no differences for the Fc-glycosylation features between the sexes. This is different from what is known for human (young) adult IgG glycosylation, where significant differences were reported for IgG Fc-galactosylation and sialylation (63).

CONCLUSION

We report pronounced differences of IgG Fc-glycosylation in mice between both subclass and strains. Especially galactosylation and sialylation showed a large variation in their abundance. In addition, the levels of hybrid structures, α 1,3-galactosylation, afucosylation, and bisection, all not previously reported on murine IgG in an Fc-specific way, showed to differ between the subclasses and strains. Noticeable variations were observed for the murine Fc-glycosylation when compared with prior-reported human Fc-glycosylation, for example, in terms of sialic acids present (respectively, Neu5Gc and Neu5Ac in mice and humans).

REFERENCES

- Murphy K, Weaver C. *Janeway's Immunobiology*. 9th ed. New York: Garland Science (2016).
- Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat Rev Immunol* (2013) 13(3):176–89. doi:10.1038/nri3401
- Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc Natl Acad Sci U S A* (2008) 105(50):19571–8. doi:10.1073/pnas.0810163105
- Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc γ RIIB and dectin-1. *Nat Med* (2012) 18(9):1401–6. doi:10.1038/nm.2862
- Bondt A, Selman MH, Deelder AM, Hazes JM, Willemsen SP, Wuhrer M, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. *J Proteome Res* (2013) 12(10):4522–31. doi:10.1021/pr400589m
- Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. *Nature* (1985) 316(6027):452–7. doi:10.1038/316452a0
- Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, et al. A functional role for antibodies in tuberculosis. *Cell* (2016) 167(2):433e–43e. doi:10.1016/j.cell.2016.08.072
- Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *J Clin Invest* (2013) 123(5):2183–92. doi:10.1172/JCI65708
- Kapur R, Della Valle L, Sonneveld M, Hipgrave Ederveen A, Visser R, Ligthart P, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. *Br J Haematol* (2014) 166(6):936–45. doi:10.1111/bjh.12965
- Kapur R, Kustiawan I, Vestreheim A, Koeleman CA, Visser R, Einarsdottir HK, et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. *Blood* (2014) 123(4):471–80. doi:10.1182/blood-2013-09-527978
- Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. *BMC Cancer* (2009) 9:58. doi:10.1186/1471-2407-9-58
- Tjon AS, van Gent R, Geijtenbeek TB, Kwekkeboom J. Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. *Front Immunol* (2015) 6:197. doi:10.3389/fimmu.2015.00197
- Chia R, Achilli F, Festing MF, Fisher EM. The origins and uses of mouse outbred stocks. *Nat Genet* (2005) 37(11):1181–6. doi:10.1038/ng1665
- Aldinger KA, Sokoloff G, Rosenberg DM, Palmer AA, Millen KJ. Genetic variation and population substructure in outbred CD-1 mice: implications for genome-wide association studies. *PLoS One* (2009) 4(3):e4729. doi:10.1371/journal.pone.0004729
- Cheemarla NR, Guerrero-Plata A. Immune response to human metapneumovirus infection: what we have learned from the mouse model. *Pathogens* (2015) 4(3):682–96. doi:10.3390/pathogens4030682

Also levels of glycosylation traits that are recognized as important immune modulators, including galactosylation, sialylation, afucosylation and bisection, deviated between humans and mice. When considering mouse models for immunological research, a careful selection should be made both on the mouse strain and on the IgG subclasses used, taking into account the baseline glycosylation profiles and biological engagement.

ETHICS STATEMENT

The mouse plasmas used in this study were obtained from commercial sources. Within the framework of the manuscript no animal experiments were performed.

AUTHOR CONTRIBUTIONS

Conceived and designed the experiments: NH, KR, and MW. Performed the experiments: NH, JK, and AH. Analyzed the data: NH, KR, and JK. Wrote the paper: NH, KR, JK, AH, GL, and MW. Supervised study: GL and MW.

FUNDING

This work was supported by the European Union Seventh Framework Programmes IBD-BIOM (grant number 305479) and HighGlycan (grant number 278535).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at <http://journal.frontiersin.org/article/10.3389/fimmu.2017.00608/full#supplementary-material>.

16. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. *Adv Cancer Res* (2010) 106:113–64. doi:10.1016/S0065-230X(10)06004-5
17. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. *Glycobiology* (2000) 10(5):477–86. doi:10.1093/glycob/10.5.477
18. Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmacic I, et al. Glycosylation of immunoglobulin G: role of genetic and epigenetic influences. *PLoS One* (2013) 8(12):e82558. doi:10.1371/journal.pone.0082558
19. Azuma K, Shinzaki S, Asazawa H, Kuroki E, Kawamoto S, Kamada Y, et al. Twin studies on the effect of genetic factors on serum agalactosyl immunoglobulin G levels. *Biomed Rep* (2014) 2(2):213–6. doi:10.3892/br.2014.216
20. Reiding KR, Hipgrave Ederveen AL, Rombouts Y, Wuhrer M. Murine plasma N-glycosylation traits associated with sex and strain. *J Proteome Res* (2016) 15(10):3489–99. doi:10.1021/acs.jproteome.6b00071
21. Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. *Glycoconj J* (2016) 33(3):309–43. doi:10.1007/s10719-015-9626-2
22. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. *Blood* (2012) 119(24):5640–9. doi:10.1182/blood-2012-01-380121
23. Maresch D, Altmann F. Isotype-specific glycosylation analysis of mouse IgG by LC-MS. *Proteomics* (2016) 16(9):1321–30. doi:10.1002/pmic.201500367
24. Zhang Z, Goldschmidt T, Salter H. Possible allelic structure of IgG2a and IgG2c in mice. *Mol Immunol* (2012) 50(3):169–71. doi:10.1016/j.molimm.2011.11.006
25. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. *J Exp Med* (2006) 203(3):743–53. doi:10.1084/jem.20052283
26. Vidarsson G, Dekkers G, Rispen T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol* (2014) 5:520. doi:10.3389/fimmu.2014.00520
27. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcγR4: a novel FcR with distinct IgG subclass specificity. *Immunity* (2005) 23(1):41–51. doi:10.1016/j.immuni.2005.05.010
28. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. *Science* (2005) 310(5753):1510–2. doi:10.1126/science.1118948
29. Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. *Anal Chem* (2014) 86(12):5784–93. doi:10.1021/ac500335t
30. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. *Mol Cell Proteomics* (2011) 10(10):M111010090. doi:10.1074/mcp.M111.010090
31. Selman MH, Hemayatkar M, Deelder AM, Wuhrer M. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. *Anal Chem* (2011) 83(7):2492–9. doi:10.1021/ac1027116
32. Jansen BC, Falck D, de Haan N, Hipgrave Ederveen AL, Razdorov G, Lauc G, et al. LaCyTools: a targeted liquid chromatography-mass spectrometry data processing package for relative quantitation of glycopeptides. *J Proteome Res* (2016) 15(7):2198–210. doi:10.1021/acs.jproteome.6b00171
33. de Haan N, Reiding KR, Driessen G, van der Burg M, Wuhrer M. Changes in healthy human IgG Fc-glycosylation after birth and during early childhood. *J Proteome Res* (2016) 15(6):1853–61. doi:10.1021/acs.jproteome.6b00038
34. Jansen BC, Reiding KR, Bondt A, Hipgrave Ederveen AL, Palmblad M, Falck D, et al. MassyTools: a high-throughput targeted data processing tool for relative quantitation and quality control developed for glycomic and glycoproteomic MALDI-MS. *J Proteome Res* (2015) 14(12):5088–98. doi:10.1021/acs.jproteome.5b00658
35. Mahan AE, Tedesco J, Dionne K, Baruah K, Cheng HD, De Jager PL, et al. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. *J Immunol Methods* (2015) 417:34–44. doi:10.1016/j.jim.2014.12.004
36. Lund J, Takahashi N, Nakagawa H, Goodall M, Bentley T, Hindley SA, et al. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. *Mol Immunol* (1993) 30(8):741–8. doi:10.1016/0161-5890(93)90145-2
37. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. *N Engl J Med* (2008) 358(11):1109–17. doi:10.1056/NEJMoa074943
38. Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ, et al. The α-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. *Transplantation* (1996) 61(1):13–9. doi:10.1097/00007890-199601150-00004
39. Varki A. Multiple changes in sialic acid biology during human evolution. *Glycoconj J* (2009) 26(3):231–45. doi:10.1007/s10719-008-9183-z
40. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. *Biochemistry* (1997) 36(6):1370–80. doi:10.1021/bi9621472
41. Pucic M, Muzinic A, Novokmet M, Skledar M, Pivac N, Lauc G, et al. Changes in plasma and IgG N-glycome during childhood and adolescence. *Glycobiology* (2012) 22(7):975–82. doi:10.1093/glycob/cws062
42. Wuhrer M, Stam JC, van de Geijn FE, Koeleman CA, Verrips CT, Dolhain RJ, et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. *Proteomics* (2007) 7(22):4070–81. doi:10.1002/pmic.200700289
43. Narasimhan S, Lee JW, Cheung RK, Gelfand EW, Schachter H. Beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase III activity in human B and T lymphocyte lines and in tonsillar B and T lymphocytes. *Biochem Cell Biol* (1988) 66(8):889–900. doi:10.1139/o88-101
44. Priatel JJ, Sarkar M, Schachter H, Marth JD. Isolation, characterization and inactivation of the mouse Mgat3 gene: the bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction. *Glycobiology* (1997) 7(1):45–56. doi:10.1093/glycob/7.1.45
45. Bhaumik M, Seldin MF, Stanley P. Cloning and chromosomal mapping of the mouse Mgat3 gene encoding N-acetylglucosaminyltransferase III. *Gene* (1995) 164(2):295–300. doi:10.1016/0378-1119(95)00260-D
46. Lanteri M, Giordanengo V, Vidal F, Gaudray P, Lefebvre JC. A complete α-1,3-galactosyltransferase gene is present in the human genome and partially transcribed. *Glycobiology* (2002) 12(12):785–92. doi:10.1093/glycob/cwf087
47. Freeze HH. Genetic defects in the human glycome. *Nat Rev Genet* (2006) 7(7):537–51. doi:10.1038/nrg1894
48. Lauc G, Huffman JE, Pucic M, Zgaga L, Adamczyk B, Muzinic A, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and hematological cancers. *PLoS Genet* (2013) 9(1):e1003225. doi:10.1371/journal.pgen.1003225
49. Dall'Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-glycomic biomarkers of biological aging and longevity: a link with inflammation. *Ageing Res Rev* (2013) 12(2):685–98. doi:10.1016/j.arr.2012.02.002
50. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. *Biotechnol Bioeng* (2001) 74(4):288–94. doi:10.1002/bit.1119.abs
51. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science* (2006) 313(5787):670–3. doi:10.1126/science.1129594
52. Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S, Harre U, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. *Nat Immunol* (2017) 18(1):104–13. doi:10.1038/ni.3579
53. Jones MB, Oswald DM, Joshi S, Whiteheart SW, Orlando R, Cobb BA. B-cell-independent sialylation of IgG. *Proc Natl Acad Sci U S A* (2016) 113(26):7207–12. doi:10.1073/pnas.1523968113
54. Hess C, Winkler A, Lorenz AK, Holeccka V, Blanchard V, Eiglmeier S, et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. *J Clin Invest* (2013) 123(9):3788–96. doi:10.1172/JCI65938
55. Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. *J Clin Invest* (2015) 125(11):4160–70. doi:10.1172/JCI82695

56. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ3R and antibody-dependent cellular toxicity. *J Biol Chem* (2002) 277(30):26733–40. doi:10.1074/jbc.M202069200
57. Brinkman-Van der Linden EC, Sjöberg ER, Juneja LR, Crocker PR, Varki N, Varki A. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. *J Biol Chem* (2000) 275(12):8633–40. doi:10.1074/jbc.275.12.8633
58. Hussain R, Dawood G, Abrar N, Toossi Z, Minai A, Dojki M, et al. Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. *Clin Diagn Lab Immunol* (1995) 2(6):726–32.
59. Burton DR. Immunoglobulin G: functional sites. *Mol Immunol* (1985) 22(3):161–206. doi:10.1016/0161-5890(85)90151-8
60. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ3R receptors and their polymorphic variants for human IgG subclasses. *Blood* (2009) 113(16):3716–25. doi:10.1182/blood-2008-09-179754
61. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. Fcγ3R is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. *J Clin Invest* (2008) 118(11):3738–50. doi:10.1172/JCI36452
62. Sengupta P. The laboratory rat: relating its age with human's. *Int J Prev Med* (2013) 4(6):624–30.
63. Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. *J Proteome Res* (2013) 12(2):821–31. doi:10.1021/pr300887z

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 de Haan, Reiding, Krištić, Hipgrave Ederveen, Lauc and Wuhrer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.